Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm IncfiledCriticalEnanta Pharm Inc
Publication of NZ601288ApublicationCriticalpatent/NZ601288A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
ABSTRACT - 601288 The disclosure relates to compounds of formula (I) and (II) pharmaceutically acceptable salts, and esters thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease, wherein the variables are as defined in the specifiation. Consequently, these compounds interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present disclosure further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection.
NZ601288A2007-11-142008-11-14Quinoxaline-containing compounds as hepatitis c virus inhibitors
NZ601288A
(en)